Literature DB >> 23765631

Emergency cardiac surgery during transfemoral and transapical transcatheter aortic valve implantation: incidence, reasons, management, and outcome of 411 patients from a single center.

Daniel P Griese1, Wilko Reents, Sebastian Kerber, Anno Diegeler, Jörg Babin-Ebell.   

Abstract

OBJECTIVES AND
BACKGROUND: Transcatheter aortic valve implantation (TAVI) is increasingly performed in high-risk patients with severe aortic valve stenosis. Incidence and impact of emergency cardiac surgery (ECS) during TAVI is unclear. METHODS AND
RESULTS: Two-hundred twenty one transapical (TA) and 190 transfemoral (TF) TAVIs were performed at our hospital between 01/2009 and 12/2012. Twenty patients (4.9%) required ECS, more frequently in the TF- (n = 11; 5.8%) than in the TA-group (n = 9; 4.1%; P = 0.017). ECS-cases were evenly distributed throughout the 4 years. Baseline characteristics of the ECS-patients were not different from the non-ECS-patients. Reasons were acute cardiac failure, coronary obstruction, annular rupture, valve migration, right- and left-ventricular perforation, severe paravalvular leakage, aortic dissection, and mitral valve damage. Surgical intervention consisted of peripheral CPB, switch to TA, thoracotomy and suture of perforated cardiac chambers and conventional aortic valve replacement with concomitant repair of associated cardiovascular injury. Thirty-day mortality was 35.0%, and 55.0% could be salvaged to hospital discharge. Kaplan-Meier 1-year survival curves were significantly impaired for patients requiring ECS (TF: P < 0.0001, HR 8.716; TA: P = 0.013, HR 2.813).
CONCLUSIONS: Life-threatening complications requiring bail-out ECS occur in a substantial proportion during TAVI. ECS dramatically affects early and late outcome after TAVI. Under optimal conditions more than half of the ECS-patients can be salvaged. With the current technology of THV-systems ECS should be an integral part of the logistic conditions surrounding TAVI and is far from being futile in this patient population.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  cardiopulmonary support; complications adult cath/intervention; valvular heart disease

Mesh:

Year:  2013        PMID: 23765631     DOI: 10.1002/ccd.25049

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  7 in total

Review 1.  Guidance of transcatheter aortic valve replacement by echocardiography.

Authors:  Rebecca T Hahn
Journal:  Curr Cardiol Rep       Date:  2014-01       Impact factor: 2.931

2.  Transcatheter aortic valve implantation at institutions without cardiovascular surgery departments: many questions still linger before a paradigm shift.

Authors:  Chiara Fraccaro; Giuseppe Tarantini
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

3.  Rupture of the aortic root : A rare but life-threatening complication of transcatheter aortic valve replacement.

Authors:  Christian Reiter; Michael Grund; Alexander Nahler; Clemens Steinwender; Thomas Lambert
Journal:  Wien Klin Wochenschr       Date:  2017-10-04       Impact factor: 1.704

4.  The Current Situation and the Future of Emergent Cardiac Surgery in TAVI.

Authors:  Holger Eggebrecht; Axel Schmermund
Journal:  Interv Cardiol       Date:  2015-03

Review 5.  Annular Rupture During Transcatheter Aortic Valve Implantation: Predictors, Management and Outcomes.

Authors:  J J Coughlan; Thomas Kiernan; Darren Mylotte; Samer Arnous
Journal:  Interv Cardiol       Date:  2018-09

6.  Late Chronic Tamponade after Intraoperative Right Ventricular Rupture Repair with Mediastinal Fat.

Authors:  Javier Gualis; Mario Castaño; Miguel Angel Rodríguez; Cristina García
Journal:  Thorac Cardiovasc Surg Rep       Date:  2015-05-18

7.  Short- and Long-Term Outcome after Emergent Cardiac Surgery during Transcatheter Aortic Valve Implantation.

Authors:  Fei Li; Xu Wang; Yuetang Wang; Xuan Li; Shihua Zhao; Yongjian Wu; Wei Wang
Journal:  Ann Thorac Cardiovasc Surg       Date:  2021-01-15       Impact factor: 1.520

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.